AR-177: ARNX will expand its clinical trial program to include a Phase I multiple-dose trial of AR-177.

Aronex Pharmaceuticals Inc. (ARNX), The Woodlands, Texas Product: AR-177 oligonucleotide targeting HIV integrase Indication: HIV Status: ARNX will expand its clinical trial program to include a Phase...